Abstract
BackgroundCAR T cell therapy has demonstrated clinical efficacy against hematological malignancies, while prominent barriers including poor T cell effector function, lack of proliferation, and limited CAR T cell persistence have...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have